Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

34.35 -0.96 (-2.72%)
Streaming Delayed Price Updated: 1:44 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
News headline image
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030 ↗
Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, while maintaining a strong generics and biosimilars base. 
Via Benzinga
News headline image
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Where Teva Pharmaceutical Indus Stands With Analysts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Billionaire Stanley Druckenmiller Just Sold One of Wall Street's Hottest Stock-Split Stocks and Is Piling Into a Promising Drugmaker Instead ↗
Duquesne Family Office's chief dumped his entire stake in one of Wall Street's premier stock-split stocks and has continued to load up on a super-cheap drug company for a third straight quarter. 
Via The Motley Fool
Topics Artificial Intelligence Economy Government
News headline image
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Why Is Teva Stock Trading Higher On Tuesday? ↗
Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design. 
Via Benzinga
News headline image
Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Why Teva Pharmaceuticals Stock Blasted 6% Higher Today ↗
Via The Motley Fool
News headline image
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
This Wayfair Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Why Teva Pharmaceutical Stock Is Soaring Today ↗
Via The Motley Fool
Topics Earnings Stocks
News headline image
Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum ↗
Teva beat Q1 EPS estimates and raised 2025 profit guidance as Austedo sales soared and margins improved, despite missing revenue expectations. 
Via Benzinga
News headline image
Teva Surges On Profit Guidance Boost Despite A Mixed First-Quarter Report ↗
Teva stock jumped early Wednesday after the drugmaker hiked its 2025 profit outlook, though trimmed its sales forecast. 
Via Investor's Business Daily
Topics Government
News headline image
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target ↗
Neurocrine stock gains as Q1 EPS beats estimates; Ingrezza sales climb 8% YoY with record new patients and strong analyst price target hikes. 
Via Benzinga
News headline image
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday? ↗
FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple chronic inflammatory diseases. 
Via Benzinga
News headline image
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
What Does the Market Think About Teva Pharmaceutical Indus? ↗
 
Via Benzinga
News headline image
Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now ↗
Short-term uncertainty has led to a golden opportunity for long-term investors. 
Via The Motley Fool
Topics Economy Government Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.